{"ticker": {"uuid": "de53b5bf-06f3-42c0-a38e-a8432935ae74", "symbol": "ELTX", "name": "Elicio Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "The article presents the enterprise value to revenue forward for Elicio Therapeutics, Inc. (NASDAQ: ELTX) on TradingView. It appears to be a financial data snippet or a specific metric displayed on the platform for the biotechnology company. The content primarily focuses on prese", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T17:39:25", "published_display": "10 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX", "summary": "Pomerantz LLP has launched an investigation into Elicio Therapeutics, Inc. (NASDAQ: ELTX) following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices after Elicio reported that its Phase 2 AMPLIFY-7P Study ", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-elicio-therapeutics-inc---eltx-302822318.html", "source_name": "PR Newswire", "published_at": "2026-07-09T17:11:20", "published_display": "09 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G/A] Elicio Therapeutics, Inc. Amended Passive Investment Disclosure", "summary": "Knoll Capital Management, Fred Knoll, and Gakasa Holdings have filed an amended Schedule 13G/A for Elicio Therapeutics, Inc. (ELTX), reporting beneficial ownership of 1,211,957 shares, which represents 5.3% of the common stock. This filing indicates shared voting and shared dispo", "url": "https://www.stocktitan.net/sec-filings/ELTX/schedule-13g-a-elicio-therapeutics-inc-amended-passive-investment-dis-2da39e830e79.html", "source_name": "Stock Titan", "published_at": "2026-07-08T18:39:15", "published_display": "08 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) after the company announced its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint, leading to a nearly 71% drop in its share price. The firm is encouraging shareholde", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1182642", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T16:39:15", "published_display": "08 Jul 2026 16:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering", "summary": "Elicio Therapeutics announced the closing of a $15 million registered direct offering. The funds, raised from new and existing institutional investors, will primarily support the planned Phase 1 clinical development of ELI-002 7P for metastatic pancreatic ductal adenocarcinoma (P", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322744/0/en/elicio-therapeutics-announces-closing-of-15-million-registered-direct-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T14:11:30", "published_display": "07 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Closes $15 Million Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/elicio-therapeutics-closes-15-million-213952388.html", "source_name": "MT Newswires", "published_at": "2026-07-06T21:39:52+00:00", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics closes $15 million stock offering", "summary": "Elicio Therapeutics has successfully closed a $15 million direct stock offering, selling 4,380,313 shares to new institutional investors and existing shareholders. The biotechnology company plans to use the proceeds, along with existing funds, for the Phase 1 clinical development", "url": "https://www.investing.com/news/company-news/elicio-therapeutics-closes-15-million-stock-offering-93CH-4777352", "source_name": "Investing.com", "published_at": "2026-07-06T21:40:10", "published_display": "06 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio closes $15M stock sale to fund KRAS cancer trial work", "summary": "Elicio Therapeutics (Nasdaq: ELTX) has successfully closed a registered direct offering, raising approximately $15 million in gross proceeds through the sale of 4,380,313 shares of common stock. These funds, secured from institutional investors and an existing shareholder, will p", "url": "https://www.stocktitan.net/news/ELTX/elicio-therapeutics-announces-closing-of-15-million-registered-kauudmvlvtlx.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:40:10", "published_display": "06 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Elicio Therapeutics, Inc. (ELTX) investors. The investigation follows a significant drop in Elicio's share price after the company announced its Phase 2 AMPLIFY-7P study did not meet its primary end", "url": "https://natlawreview.com/press-releases/elicio-therapeutics-inc-eltx-investigation-bronstein-gewirtz-grossman-llc-0", "source_name": "The National Law Review", "published_at": "2026-07-05T16:12:05", "published_display": "05 Jul 2026 16:12", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "This page provides financial information for Elicio Therapeutics, Inc. (NASDAQ: ELTX), specifically focusing on its enterprise value to EBIT forward ratio. The content appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. H", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:09:03", "published_display": "05 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxOcHNYNW00WmZRNUNCcGk3MEVDNlh3TEg4dGxVME1kMFNtcnRtWDM0Wkp4Z08tOTBQVktOT2U0X3RkZjFLbnA0ay1SVnd6RnpINm5pT1ZRT0dwVzFuTmpLNG1vX01uZUpFZTNMQVMyaDZlaUlUU2VoOWNQeXJBQVRKeHE3RkgwRTlSOGFWbmhOdmVZVjNKMDMyaEhyTEk4QXhsVDVraUdzWUtvRmsweFNjVkFsTUlyZHd6eFp2WXJEcm96aS1VZGt4LXZqM0lvWUNXQ051Vy1yd19XT2M2eXgwQ2Q4TFZUY3JsTVdwZTI2UFVvUGs1TjV5d05VdDVSSElsY0kwQWhaODdGVFg1dW5LMTh6S1Y1dzNTZi1FemR4MVpyNlBUd09r?oc=5", "source_name": "Moomoo", "published_at": "2026-07-04T05:14:26+00:00", "published_display": "04 Jul 2026 05:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "This page displays the \"Price to sales forward\" metric for Elicio Therapeutics, Inc. (NASDAQ: ELTX) on TradingView. It indicates that the market was closed with no trades at the time of viewing. The content provides navigational elements and company information related to Trading", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T04:39:22", "published_display": "04 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics stock tumbles on $15M offering By Investing.com", "summary": "Elicio Therapeutics Inc. (NASDAQ:ELTX) shares dropped 32.5% after announcing a $15 million registered direct offering. The funding, led by new institutional investors and an existing shareholder, will support the Phase 1 clinical development of ELI-002 7P for metastatic pancreati", "url": "https://m.za.investing.com/news/stock-market-news/elicio-therapeutics-stock-tumbles-on-15m-offering-93CH-4354192?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-02T15:09:49", "published_display": "02 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Intends to Use Net Proceeds From Offering to Fund Clinical Development >ELTX", "summary": "Elicio Therapeutics plans to utilize the net proceeds from a public offering of common stock, pre-funded warrants, and common warrants to further fund the clinical development of its pipeline. A significant portion of these funds will be allocated towards advancing ELI-002, the c", "url": "https://www.moomoo.com/news/post/72372080/elicio-therapeutics-intends-to-use-net-proceeds-from-offering-to", "source_name": "Moomoo", "published_at": "2026-07-02T13:10:10", "published_display": "02 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) raises ~$15.0M via 4.38M-share placement", "summary": "Elicio Therapeutics (ELTX) has raised approximately $15.0 million through a registered offering of 4.38 million shares at $3.43 per share. The net proceeds of $13.6 million will primarily fund a planned Phase 1 study for ELI-002 7P in metastatic pancreatic cancer, advance its pip", "url": "https://www.stocktitan.net/sec-filings/ELTX/424b5-elicio-therapeutics-inc-prospectus-supplement-debt-securities-32d10a8ce235.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:39:22", "published_display": "02 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Elicio Therapeutics,", "summary": "Elicio Therapeutics has filed a Form 424B5 prospectus supplement for the offering of 4,380,313 shares of common stock, aiming to raise approximately $13.6 million in net proceeds. The company, a clinical-stage biotechnology firm, plans to use these proceeds to fund the Phase 1 cl", "url": "https://www.streetinsider.com/SEC+Filings/Form+424B5+Elicio+Therapeutics%2C/26724301.html", "source_name": "StreetInsider", "published_at": "2026-07-02T12:09:49", "published_display": "02 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) prices $15M registered direct equity offering", "summary": "Elicio Therapeutics (ELTX) has announced the pricing of a $15 million registered direct offering of 4,380,313 shares of common stock at $3.43 per share. The biotech company plans to use the net proceeds, along with its existing cash, primarily to fund the planned Phase 1 clinical", "url": "https://www.stocktitan.net/sec-filings/ELTX/8-k-elicio-therapeutics-inc-reports-material-event-31b830f3a106.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:40:02", "published_display": "02 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Prices $15 Million Registered Direct Offering at $3.43; Signs Purchase, Placement Pacts", "summary": "Elicio Therapeutics has announced a $15 million registered direct offering of 4,380,313 common shares priced at $3.43 each, expected to close on July 6, 2026. The company has entered into a Securities Purchase Agreement with institutional investors and a separate Placement Agency", "url": "https://www.tradingview.com/news/tradingview:3bbcf77ec16f2:0-elicio-therapeutics-prices-15-million-registered-direct-offering-at-3-43-signs-purchase-placement-pacts/", "source_name": "TradingView", "published_at": "2026-07-02T10:40:02", "published_display": "02 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOLXVENzZnU3haQzgzUzNvRl9GYXR1cklNbVBIT0lEbUNSUVpIR3g4aGt5T3BKRlJkdHQ4NVBtWlh5THhRTi01S2VnZE1uMWRlQTdxb1VEcEN6SUNkMzFMX19ONDA3bzFPdlNsbG1GZmJXT19LQUNmZGVYT0NVSXc0ZTNObmNaR05zVFRCY2RjakxjR0V0UWFN?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Prices $15 Million Direct Offering", "summary": "Elicio Therapeutics has priced a $15 million direct offering. The company is a clinical-stage biotechnology firm developing immunotherapies for cancer, including vaccines targeting mutated KRAS, BRAF, and TP53. Recent news includes mixed results from their ELI-002 Phase 2 study f", "url": "https://www.marketscreener.com/news/elicio-therapeutics-prices-15-million-direct-offering-ce7f5fd2de80f222", "source_name": "marketscreener.com", "published_at": "2026-07-02T07:40:02", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio locks in $15M to fund Phase 1 KRAS cancer trial", "summary": "Elicio Therapeutics (Nasdaq: ELTX) announced a registered direct offering to raise approximately $15 million. The funding, led by new institutional investors and a large existing shareholder, will primarily support the planned Phase 1 development of ELI-002 7P for metastatic PDAC", "url": "https://www.stocktitan.net/news/ELTX/elicio-therapeutics-announces-pricing-of-15-million-registered-0071phd0k5ro.html", "source_name": "Stock Titan", "published_at": "2026-07-02T06:40:02", "published_display": "02 Jul 2026 06:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics raises $15M in registered direct offering", "summary": "Elicio Therapeutics (NASDAQ:ELTX) has announced a registered direct offering to raise approximately $15 million from two new institutional investors and an existing shareholder. The funds will be used to advance the Phase 1 clinical development of ELI-002 7P for metastatic pancre", "url": "https://www.investing.com/news/company-news/elicio-therapeutics-raises-15m-in-registered-direct-offering-93CH-4772282", "source_name": "Investing.com", "published_at": "2026-07-02T04:40:02", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering", "summary": "Elicio Therapeutics has announced the pricing of a registered direct offering totaling $15 million, led by new institutional investors and an existing shareholder. The proceeds will primarily fund the Phase 1 clinical development of ELI-002 7P for metastatic PDAC, expand Elicio\u2019s", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321078/0/en/elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T04:40:02", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces $15 Million Registered Direct Offering to Fund ELI-002 7P Clinical Development", "summary": "Elicio Therapeutics has announced a $15 million registered direct offering to fund the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, with new institutional investors and an existing shareholder participating. The net proceeds, along with existing ca", "url": "https://www.quiverquant.com/news/Elicio+Therapeutics+Announces+%2415+Million+Registered+Direct+Offering+to+Fund+ELI-002+7P+Clinical+Development", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T04:30:00", "published_display": "02 Jul 2026 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "This page from TradingView provides financial information for Elicio Therapeutics, Inc. (NASDAQ: ELTX), specifically focusing on its forward price-to-book ratio. The content appears to be a financial data page rather than a detailed news article, offering an overview of the compa", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:40:02", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) following a significant drop in its share price. This investigation comes after Elicio announced that its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint of disease", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1182636", "source_name": "ACCESS Newswire", "published_at": "2026-07-01T16:39:13", "published_display": "01 Jul 2026 16:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therap", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elicio Therapeutics, Inc. (NASDAQ:ELTX) after the company announced its Phase 2 AMPLIFY-7P study did not meet its primary endpoint of disease-free survival, causing shares to fall by a", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-elicio-therapeutics-inc-eltx", "source_name": "The National Law Review", "published_at": "2026-06-30T15:09:39", "published_display": "30 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2500 Growth Benchmark", "summary": "Elicio Therapeutics, Inc. (ELTX) has been added to the Russell 2500 Growth Benchmark. The clinical-stage biotechnology company focuses on developing immunotherapies for cancer, utilizing its amphiphile (AMP) platform to deliver immunotherapeutics directly to lymph nodes. The comp", "url": "https://www.marketscreener.com/news/elicio-therapeutics-inc-nasdaqcm-eltx-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89ff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:40:38", "published_display": "29 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) following a significant 71% drop in its share price. This decline occurred after the company announced that its Phase 2 AMPLIFY-7P study did not meet its primary endpoint of dis", "url": "https://natlawreview.com/press-releases/elicio-therapeutics-inc-eltx-investigation-bronstein-gewirtz-grossman-llc", "source_name": "The National Law Review", "published_at": "2026-06-29T15:40:37", "published_display": "29 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Added to Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/elicio-therapeutics-added-russell-2000-120000655.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:00:00+00:00", "published_display": "29 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics added to Russell 2000 and 3000 indexes", "summary": "Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company, has been added to the Russell 2000 and Russell 3000 indexes. This inclusion aims to boost the company's visibility among institutional investors, despite its stock trading at $4, a 50% decrease over the pa", "url": "https://www.investing.com/news/company-news/elicio-therapeutics-added-to-russell-2000-and-3000-indexes-93CH-4765215", "source_name": "Investing.com", "published_at": "2026-06-29T12:41:10", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics joins Russell indexes after annual reconstitution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQX0Y2aElzWHZjQkxFdUJnN2lINmxUbWNXRW5XWS1rN0pIWFZuUWtlYWM4Y3daVnpxN2I4WF9ncnJ6YkdmM05nRDlRM0N2amc1V1FkdVFJQUM5QjVFX1dfekxsbUtDQWMtQm8zWGlHazVMMTBraGNMQ3VIajFVNkNLaDVHT3R3LUlTcnNoZ0xISzlqeHo2MzRmU3c2d0NhcElJWG1UQzVuUW1DbnZaeXo3OW5DQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQNWNwUktuTHdxMUtKcHR5SU0zVlpLZ0JMT3lOMWxXSTJ6X0YwSFNtdDRDZFQyVHFzVkJCZUt6TzhDelBIZkx0eUVuT0xtOGM0cDd5ald0b0l1N2djTk52MnRPdnRrQ2FiODZlS0NqNy16ZGdybTdOTXpYUGp6bXVWckFkVm52bGcwRlBoQXdaa3NER0xuY29NZXB5aFBzZEZDNnk5cGxqeTFvanV2ODRjX3VwQVEwMGVCeHEzUGN1blFMdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Reports Complete Responses in 3 Pancreatic Cancer Patients After ELI-002 7P, Nivolumab Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/elicio-reports-complete-responses-3-142042945.html", "source_name": "MT Newswires", "published_at": "2026-06-17T14:20:42+00:00", "published_display": "17 Jun 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three complete responses in metastatic PDAC spur new Elicio (NASDAQ: ELTX) trial plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSEtNUXZ2Qi1qX2N2SU9WTkFJeS1CaW1UMEY4aFhhMnROLTRpZGFxdi1aeHR3eVdrckxGdHJHeHlQczUwZkxLUHV3bEttTHVCcXhObTdSdnhpSk1STlc1TlhPSF92S1ZJc1RLSW9wWF9aR091a19pNWQ3cHdIZ3RwUDhNYTEzUkRtZjhRTXNwc2Y0NjBZeTJ1b3hQM1d2TjMwT3RqWDFqUXFhWUZodHYwRGRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics rebounds as investors refocus on subgroup data and a revised Phase 3 plan | ELTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbENoVDRTMlJBdXV4QlloTWhtRWRRT1h3cVcwWkczOTZkMDNhaXNrcFZWMUVMQndfTDlRSDBtLXJpSms5OUs0bjR0OHRMWGd1eUx6SURZaEFERi0yeEhod2hKTldCRG1RTV9FOWpzV3Zob2stbF92SDA1Y3BydkdFNHdHOVUxeWlQeDhpc2RCLVVQYm9MRlUxMWdseGZVWWFaVHhOYWphNzBrNk9NN3BndWd2aE9ZTWFINzlrLVR6QUtCdVQ2?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics\u2019 Shares Drop Following Announcement of Phase II Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOOUFZY3JxYkVCWUROWlBOUW1kbTRzQ2lfd3BUamVkUW8zaGJLOTM3a3lKN3Q3SzNkejFxc2VYWDE0MzBNdWFvem1hb0hCYmRNR0M3UllJSG42ZFRRWXVDNF8zOTg1cmoyRkFXZ0staUprTEpqU2NMLXBRdWx0VWNtdDBoQlBoX24wWWk5XzhB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) Is Down 69.9% After Phase 2 ELI-002 Miss in Pancreatic Cancer Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELTX Stock Heads For Worst Day Ever \u2014 Elicio Therapeutics' Pancreatic Cancer Data Disappoints", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNODUyTGlydG1Cci1fd0MzMndHb0VvbXlWVEFCbUxOdklRaTRhd3hOU2pXTlhhTDNBVUpQRkwwaHZNRHhLWEx0N0xSbTZlQzlVTTVXYnpBV01ENlJsTnU0WHZCYnFYQ1ZvS0l0MDJ4ZTh0Rlh4OVp4WGxfYXZvQjNFaEZ4NUpWZTM0MFk5eFlHb1FnYU45WnRvOTQyc2lwaEdpSTA2U0w4cTlLRDM4NUJ0cDJmRHBpZVVVaDZXNmd3NHplbVdYUGZmMTZFTC15WGU1ZlZyanFwdUEwY3RfRVBpMnQ2SEFXU1BTRVE?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQbG9LNmJ4M2xJcWlUam45M2N1MXQ2UGpFUUNOdm1oSVlteFI4UTl6Q0FOOHd5c1pLM3NFRmxRSjliWkRiUExuODVmbF95c2M3el9BXzlHWktlWm1ZcmJDcEYydHVNM0N0WHFITVZpbFRMcTlJak5pT09VMWVpR0NHR0JZWVB2b1Q3dXpuRlI4eFdITnl6VWlVeEZlZGJoNVNaVmVfM05neUg3QWs3X0JVZTJvdw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Elicio Therapeutics to Present at the Bank of America Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxObXAtZFU2Q2g3Q25hQzlXaVZlV3ctSy1CRUdCS0hYSnJNS2d1Zkxabjg5ZThPc3hPRkYwcWRaVXFoYmMwbmQwNFFPTUN1UDAzY3l1aC1Ha1pZRHZaMlFKVmFCUjVQRmtTT0FOajNTU0V6dVVyVVN3eGVFUVY0NjVoZ2RFLVdfb1oyYnYweFZNeXVzVmM0Nk5aYXdROTE5WWp0ZFE4UUp1OUdWMU83UjRURDB4elJVNzBqSlRISGwxeElacGVpNVk3akhRSmJJbFQxWlVXZ0d6NG8tVmktZHlmdQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Elicio Therapeutics Reports Inducement Grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNRWUySTF3WnRHaW40eV92Vk5ldTRtVHpicmJvZzcydDhZbVJveEJ4a0lTTm9MZWVIRElfNVVQcURZUnJiWmZKajV0TVBrajNUakU0WklDZHBLaDJoamtrbGhyMlhtdU9La3Z0UF94VkJwbjg1QjJjUjNoSjJ0SURVZmkydnVPRGJOckE?oc=5", "source_name": "Elicio Therapeutics", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces $6.0 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQYzcwRGxxRU51UlZLVVlsS0xoQ0lyWmVhWEVPb2VvU19wMGt1SW1PQ0Y4TXdXb1ZFbDR6QWd0MU84ZUFyS2Y5T3pJUGxSQm9ZUWpXajdqcDE2dWk3RFo3aS05bVc1T1RNb0wzazJJeWRpamQ0bmh2RHFUUzVBSF82UTBXN2ZvM01hSjNVNUNLeXQyRzFlVmNSREctVTNqZUpTOXdfVy1LZw?oc=5", "source_name": "Elicio Therapeutics", "published_at": "2024-03-18T07:00:00+00:00", "published_display": "18 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBOaTJIWU13SENWdHkzY1F4c1YwelA1WUxyeUxVZjV5V3pxQkNjSkN0X1FEN0p0amZvU3lITXFuWm1HMHlfOFdTaTlnUG5ad3pkeE90MmFQOGFyUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-07-27T14:57:04+00:00", "published_display": "27 Jul 2021 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to revenue forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "The article presents the enterprise value to revenue forward for Elicio Therapeutics, Inc. (NASDAQ: ELTX) on TradingView. It appears to be a financial data snippet or a specific metric displayed on the platform for the biotechnology company. The content primarily focuses on prese", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T17:39:25", "published_display": "10 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX", "summary": "Pomerantz LLP has launched an investigation into Elicio Therapeutics, Inc. (NASDAQ: ELTX) following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices after Elicio reported that its Phase 2 AMPLIFY-7P Study ", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-elicio-therapeutics-inc---eltx-302822318.html", "source_name": "PR Newswire", "published_at": "2026-07-09T17:11:20", "published_display": "09 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G/A] Elicio Therapeutics, Inc. Amended Passive Investment Disclosure", "summary": "Knoll Capital Management, Fred Knoll, and Gakasa Holdings have filed an amended Schedule 13G/A for Elicio Therapeutics, Inc. (ELTX), reporting beneficial ownership of 1,211,957 shares, which represents 5.3% of the common stock. This filing indicates shared voting and shared dispo", "url": "https://www.stocktitan.net/sec-filings/ELTX/schedule-13g-a-elicio-therapeutics-inc-amended-passive-investment-dis-2da39e830e79.html", "source_name": "Stock Titan", "published_at": "2026-07-08T18:39:15", "published_display": "08 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) after the company announced its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint, leading to a nearly 71% drop in its share price. The firm is encouraging shareholde", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1182642", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T16:39:15", "published_display": "08 Jul 2026 16:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering", "summary": "Elicio Therapeutics announced the closing of a $15 million registered direct offering. The funds, raised from new and existing institutional investors, will primarily support the planned Phase 1 clinical development of ELI-002 7P for metastatic pancreatic ductal adenocarcinoma (P", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322744/0/en/elicio-therapeutics-announces-closing-of-15-million-registered-direct-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T14:11:30", "published_display": "07 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Closes $15 Million Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/elicio-therapeutics-closes-15-million-213952388.html", "source_name": "MT Newswires", "published_at": "2026-07-06T21:39:52+00:00", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics closes $15 million stock offering", "summary": "Elicio Therapeutics has successfully closed a $15 million direct stock offering, selling 4,380,313 shares to new institutional investors and existing shareholders. The biotechnology company plans to use the proceeds, along with existing funds, for the Phase 1 clinical development", "url": "https://www.investing.com/news/company-news/elicio-therapeutics-closes-15-million-stock-offering-93CH-4777352", "source_name": "Investing.com", "published_at": "2026-07-06T21:40:10", "published_display": "06 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio closes $15M stock sale to fund KRAS cancer trial work", "summary": "Elicio Therapeutics (Nasdaq: ELTX) has successfully closed a registered direct offering, raising approximately $15 million in gross proceeds through the sale of 4,380,313 shares of common stock. These funds, secured from institutional investors and an existing shareholder, will p", "url": "https://www.stocktitan.net/news/ELTX/elicio-therapeutics-announces-closing-of-15-million-registered-kauudmvlvtlx.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:40:10", "published_display": "06 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Elicio Therapeutics, Inc. (ELTX) investors. The investigation follows a significant drop in Elicio's share price after the company announced its Phase 2 AMPLIFY-7P study did not meet its primary end", "url": "https://natlawreview.com/press-releases/elicio-therapeutics-inc-eltx-investigation-bronstein-gewirtz-grossman-llc-0", "source_name": "The National Law Review", "published_at": "2026-07-05T16:12:05", "published_display": "05 Jul 2026 16:12", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "This page provides financial information for Elicio Therapeutics, Inc. (NASDAQ: ELTX), specifically focusing on its enterprise value to EBIT forward ratio. The content appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. H", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:09:03", "published_display": "05 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxOcHNYNW00WmZRNUNCcGk3MEVDNlh3TEg4dGxVME1kMFNtcnRtWDM0Wkp4Z08tOTBQVktOT2U0X3RkZjFLbnA0ay1SVnd6RnpINm5pT1ZRT0dwVzFuTmpLNG1vX01uZUpFZTNMQVMyaDZlaUlUU2VoOWNQeXJBQVRKeHE3RkgwRTlSOGFWbmhOdmVZVjNKMDMyaEhyTEk4QXhsVDVraUdzWUtvRmsweFNjVkFsTUlyZHd6eFp2WXJEcm96aS1VZGt4LXZqM0lvWUNXQ051Vy1yd19XT2M2eXgwQ2Q4TFZUY3JsTVdwZTI2UFVvUGs1TjV5d05VdDVSSElsY0kwQWhaODdGVFg1dW5LMTh6S1Y1dzNTZi1FemR4MVpyNlBUd09r?oc=5", "source_name": "Moomoo", "published_at": "2026-07-04T05:14:26+00:00", "published_display": "04 Jul 2026 05:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "This page displays the \"Price to sales forward\" metric for Elicio Therapeutics, Inc. (NASDAQ: ELTX) on TradingView. It indicates that the market was closed with no trades at the time of viewing. The content provides navigational elements and company information related to Trading", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T04:39:22", "published_display": "04 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics stock tumbles on $15M offering By Investing.com", "summary": "Elicio Therapeutics Inc. (NASDAQ:ELTX) shares dropped 32.5% after announcing a $15 million registered direct offering. The funding, led by new institutional investors and an existing shareholder, will support the Phase 1 clinical development of ELI-002 7P for metastatic pancreati", "url": "https://m.za.investing.com/news/stock-market-news/elicio-therapeutics-stock-tumbles-on-15m-offering-93CH-4354192?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-02T15:09:49", "published_display": "02 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Intends to Use Net Proceeds From Offering to Fund Clinical Development >ELTX", "summary": "Elicio Therapeutics plans to utilize the net proceeds from a public offering of common stock, pre-funded warrants, and common warrants to further fund the clinical development of its pipeline. A significant portion of these funds will be allocated towards advancing ELI-002, the c", "url": "https://www.moomoo.com/news/post/72372080/elicio-therapeutics-intends-to-use-net-proceeds-from-offering-to", "source_name": "Moomoo", "published_at": "2026-07-02T13:10:10", "published_display": "02 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) raises ~$15.0M via 4.38M-share placement", "summary": "Elicio Therapeutics (ELTX) has raised approximately $15.0 million through a registered offering of 4.38 million shares at $3.43 per share. The net proceeds of $13.6 million will primarily fund a planned Phase 1 study for ELI-002 7P in metastatic pancreatic cancer, advance its pip", "url": "https://www.stocktitan.net/sec-filings/ELTX/424b5-elicio-therapeutics-inc-prospectus-supplement-debt-securities-32d10a8ce235.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:39:22", "published_display": "02 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Elicio Therapeutics,", "summary": "Elicio Therapeutics has filed a Form 424B5 prospectus supplement for the offering of 4,380,313 shares of common stock, aiming to raise approximately $13.6 million in net proceeds. The company, a clinical-stage biotechnology firm, plans to use these proceeds to fund the Phase 1 cl", "url": "https://www.streetinsider.com/SEC+Filings/Form+424B5+Elicio+Therapeutics%2C/26724301.html", "source_name": "StreetInsider", "published_at": "2026-07-02T12:09:49", "published_display": "02 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) prices $15M registered direct equity offering", "summary": "Elicio Therapeutics (ELTX) has announced the pricing of a $15 million registered direct offering of 4,380,313 shares of common stock at $3.43 per share. The biotech company plans to use the net proceeds, along with its existing cash, primarily to fund the planned Phase 1 clinical", "url": "https://www.stocktitan.net/sec-filings/ELTX/8-k-elicio-therapeutics-inc-reports-material-event-31b830f3a106.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:40:02", "published_display": "02 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Prices $15 Million Registered Direct Offering at $3.43; Signs Purchase, Placement Pacts", "summary": "Elicio Therapeutics has announced a $15 million registered direct offering of 4,380,313 common shares priced at $3.43 each, expected to close on July 6, 2026. The company has entered into a Securities Purchase Agreement with institutional investors and a separate Placement Agency", "url": "https://www.tradingview.com/news/tradingview:3bbcf77ec16f2:0-elicio-therapeutics-prices-15-million-registered-direct-offering-at-3-43-signs-purchase-placement-pacts/", "source_name": "TradingView", "published_at": "2026-07-02T10:40:02", "published_display": "02 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOLXVENzZnU3haQzgzUzNvRl9GYXR1cklNbVBIT0lEbUNSUVpIR3g4aGt5T3BKRlJkdHQ4NVBtWlh5THhRTi01S2VnZE1uMWRlQTdxb1VEcEN6SUNkMzFMX19ONDA3bzFPdlNsbG1GZmJXT19LQUNmZGVYT0NVSXc0ZTNObmNaR05zVFRCY2RjakxjR0V0UWFN?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Prices $15 Million Direct Offering", "summary": "Elicio Therapeutics has priced a $15 million direct offering. The company is a clinical-stage biotechnology firm developing immunotherapies for cancer, including vaccines targeting mutated KRAS, BRAF, and TP53. Recent news includes mixed results from their ELI-002 Phase 2 study f", "url": "https://www.marketscreener.com/news/elicio-therapeutics-prices-15-million-direct-offering-ce7f5fd2de80f222", "source_name": "marketscreener.com", "published_at": "2026-07-02T07:40:02", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio locks in $15M to fund Phase 1 KRAS cancer trial", "summary": "Elicio Therapeutics (Nasdaq: ELTX) announced a registered direct offering to raise approximately $15 million. The funding, led by new institutional investors and a large existing shareholder, will primarily support the planned Phase 1 development of ELI-002 7P for metastatic PDAC", "url": "https://www.stocktitan.net/news/ELTX/elicio-therapeutics-announces-pricing-of-15-million-registered-0071phd0k5ro.html", "source_name": "Stock Titan", "published_at": "2026-07-02T06:40:02", "published_display": "02 Jul 2026 06:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics raises $15M in registered direct offering", "summary": "Elicio Therapeutics (NASDAQ:ELTX) has announced a registered direct offering to raise approximately $15 million from two new institutional investors and an existing shareholder. The funds will be used to advance the Phase 1 clinical development of ELI-002 7P for metastatic pancre", "url": "https://www.investing.com/news/company-news/elicio-therapeutics-raises-15m-in-registered-direct-offering-93CH-4772282", "source_name": "Investing.com", "published_at": "2026-07-02T04:40:02", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering", "summary": "Elicio Therapeutics has announced the pricing of a registered direct offering totaling $15 million, led by new institutional investors and an existing shareholder. The proceeds will primarily fund the Phase 1 clinical development of ELI-002 7P for metastatic PDAC, expand Elicio\u2019s", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321078/0/en/elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T04:40:02", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces $15 Million Registered Direct Offering to Fund ELI-002 7P Clinical Development", "summary": "Elicio Therapeutics has announced a $15 million registered direct offering to fund the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, with new institutional investors and an existing shareholder participating. The net proceeds, along with existing ca", "url": "https://www.quiverquant.com/news/Elicio+Therapeutics+Announces+%2415+Million+Registered+Direct+Offering+to+Fund+ELI-002+7P+Clinical+Development", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T04:30:00", "published_display": "02 Jul 2026 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX", "summary": "This page from TradingView provides financial information for Elicio Therapeutics, Inc. (NASDAQ: ELTX), specifically focusing on its forward price-to-book ratio. The content appears to be a financial data page rather than a detailed news article, offering an overview of the compa", "url": "https://www.tradingview.com/symbols/NASDAQ-ELTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:40:02", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) following a significant drop in its share price. This investigation comes after Elicio announced that its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint of disease", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1182636", "source_name": "ACCESS Newswire", "published_at": "2026-07-01T16:39:13", "published_display": "01 Jul 2026 16:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therap", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elicio Therapeutics, Inc. (NASDAQ:ELTX) after the company announced its Phase 2 AMPLIFY-7P study did not meet its primary endpoint of disease-free survival, causing shares to fall by a", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-elicio-therapeutics-inc-eltx", "source_name": "The National Law Review", "published_at": "2026-06-30T15:09:39", "published_display": "30 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2500 Growth Benchmark", "summary": "Elicio Therapeutics, Inc. (ELTX) has been added to the Russell 2500 Growth Benchmark. The clinical-stage biotechnology company focuses on developing immunotherapies for cancer, utilizing its amphiphile (AMP) platform to deliver immunotherapeutics directly to lymph nodes. The comp", "url": "https://www.marketscreener.com/news/elicio-therapeutics-inc-nasdaqcm-eltx-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89ff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:40:38", "published_display": "29 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) following a significant 71% drop in its share price. This decline occurred after the company announced that its Phase 2 AMPLIFY-7P study did not meet its primary endpoint of dis", "url": "https://natlawreview.com/press-releases/elicio-therapeutics-inc-eltx-investigation-bronstein-gewirtz-grossman-llc", "source_name": "The National Law Review", "published_at": "2026-06-29T15:40:37", "published_display": "29 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Added to Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/elicio-therapeutics-added-russell-2000-120000655.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:00:00+00:00", "published_display": "29 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics added to Russell 2000 and 3000 indexes", "summary": "Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company, has been added to the Russell 2000 and Russell 3000 indexes. This inclusion aims to boost the company's visibility among institutional investors, despite its stock trading at $4, a 50% decrease over the pa", "url": "https://www.investing.com/news/company-news/elicio-therapeutics-added-to-russell-2000-and-3000-indexes-93CH-4765215", "source_name": "Investing.com", "published_at": "2026-06-29T12:41:10", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics joins Russell indexes after annual reconstitution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQX0Y2aElzWHZjQkxFdUJnN2lINmxUbWNXRW5XWS1rN0pIWFZuUWtlYWM4Y3daVnpxN2I4WF9ncnJ6YkdmM05nRDlRM0N2amc1V1FkdVFJQUM5QjVFX1dfekxsbUtDQWMtQm8zWGlHazVMMTBraGNMQ3VIajFVNkNLaDVHT3R3LUlTcnNoZ0xISzlqeHo2MzRmU3c2d0NhcElJWG1UQzVuUW1DbnZaeXo3OW5DQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQNWNwUktuTHdxMUtKcHR5SU0zVlpLZ0JMT3lOMWxXSTJ6X0YwSFNtdDRDZFQyVHFzVkJCZUt6TzhDelBIZkx0eUVuT0xtOGM0cDd5ald0b0l1N2djTk52MnRPdnRrQ2FiODZlS0NqNy16ZGdybTdOTXpYUGp6bXVWckFkVm52bGcwRlBoQXdaa3NER0xuY29NZXB5aFBzZEZDNnk5cGxqeTFvanV2ODRjX3VwQVEwMGVCeHEzUGN1blFMdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Reports Complete Responses in 3 Pancreatic Cancer Patients After ELI-002 7P, Nivolumab Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/elicio-reports-complete-responses-3-142042945.html", "source_name": "MT Newswires", "published_at": "2026-06-17T14:20:42+00:00", "published_display": "17 Jun 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three complete responses in metastatic PDAC spur new Elicio (NASDAQ: ELTX) trial plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSEtNUXZ2Qi1qX2N2SU9WTkFJeS1CaW1UMEY4aFhhMnROLTRpZGFxdi1aeHR3eVdrckxGdHJHeHlQczUwZkxLUHV3bEttTHVCcXhObTdSdnhpSk1STlc1TlhPSF92S1ZJc1RLSW9wWF9aR091a19pNWQ3cHdIZ3RwUDhNYTEzUkRtZjhRTXNwc2Y0NjBZeTJ1b3hQM1d2TjMwT3RqWDFqUXFhWUZodHYwRGRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics rebounds as investors refocus on subgroup data and a revised Phase 3 plan | ELTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbENoVDRTMlJBdXV4QlloTWhtRWRRT1h3cVcwWkczOTZkMDNhaXNrcFZWMUVMQndfTDlRSDBtLXJpSms5OUs0bjR0OHRMWGd1eUx6SURZaEFERi0yeEhod2hKTldCRG1RTV9FOWpzV3Zob2stbF92SDA1Y3BydkdFNHdHOVUxeWlQeDhpc2RCLVVQYm9MRlUxMWdseGZVWWFaVHhOYWphNzBrNk9NN3BndWd2aE9ZTWFINzlrLVR6QUtCdVQ2?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics\u2019 Shares Drop Following Announcement of Phase II Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOOUFZY3JxYkVCWUROWlBOUW1kbTRzQ2lfd3BUamVkUW8zaGJLOTM3a3lKN3Q3SzNkejFxc2VYWDE0MzBNdWFvem1hb0hCYmRNR0M3UllJSG42ZFRRWXVDNF8zOTg1cmoyRkFXZ0staUprTEpqU2NMLXBRdWx0VWNtdDBoQlBoX24wWWk5XzhB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) Is Down 69.9% After Phase 2 ELI-002 Miss in Pancreatic Cancer Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELTX Stock Heads For Worst Day Ever \u2014 Elicio Therapeutics' Pancreatic Cancer Data Disappoints", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNODUyTGlydG1Cci1fd0MzMndHb0VvbXlWVEFCbUxOdklRaTRhd3hOU2pXTlhhTDNBVUpQRkwwaHZNRHhLWEx0N0xSbTZlQzlVTTVXYnpBV01ENlJsTnU0WHZCYnFYQ1ZvS0l0MDJ4ZTh0Rlh4OVp4WGxfYXZvQjNFaEZ4NUpWZTM0MFk5eFlHb1FnYU45WnRvOTQyc2lwaEdpSTA2U0w4cTlLRDM4NUJ0cDJmRHBpZVVVaDZXNmd3NHplbVdYUGZmMTZFTC15WGU1ZlZyanFwdUEwY3RfRVBpMnQ2SEFXU1BTRVE?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQbG9LNmJ4M2xJcWlUam45M2N1MXQ2UGpFUUNOdm1oSVlteFI4UTl6Q0FOOHd5c1pLM3NFRmxRSjliWkRiUExuODVmbF95c2M3el9BXzlHWktlWm1ZcmJDcEYydHVNM0N0WHFITVZpbFRMcTlJak5pT09VMWVpR0NHR0JZWVB2b1Q3dXpuRlI4eFdITnl6VWlVeEZlZGJoNVNaVmVfM05neUg3QWs3X0JVZTJvdw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics to Present at the Bank of America Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxObXAtZFU2Q2g3Q25hQzlXaVZlV3ctSy1CRUdCS0hYSnJNS2d1Zkxabjg5ZThPc3hPRkYwcWRaVXFoYmMwbmQwNFFPTUN1UDAzY3l1aC1Ha1pZRHZaMlFKVmFCUjVQRmtTT0FOajNTU0V6dVVyVVN3eGVFUVY0NjVoZ2RFLVdfb1oyYnYweFZNeXVzVmM0Nk5aYXdROTE5WWp0ZFE4UUp1OUdWMU83UjRURDB4elJVNzBqSlRISGwxeElacGVpNVk3akhRSmJJbFQxWlVXZ0d6NG8tVmktZHlmdQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Reports Inducement Grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNRWUySTF3WnRHaW40eV92Vk5ldTRtVHpicmJvZzcydDhZbVJveEJ4a0lTTm9MZWVIRElfNVVQcURZUnJiWmZKajV0TVBrajNUakU0WklDZHBLaDJoamtrbGhyMlhtdU9La3Z0UF94VkJwbjg1QjJjUjNoSjJ0SURVZmkydnVPRGJOckE?oc=5", "source_name": "Elicio Therapeutics", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics Announces $6.0 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQYzcwRGxxRU51UlZLVVlsS0xoQ0lyWmVhWEVPb2VvU19wMGt1SW1PQ0Y4TXdXb1ZFbDR6QWd0MU84ZUFyS2Y5T3pJUGxSQm9ZUWpXajdqcDE2dWk3RFo3aS05bVc1T1RNb0wzazJJeWRpamQ0bmh2RHFUUzVBSF82UTBXN2ZvM01hSjNVNUNLeXQyRzFlVmNSREctVTNqZUpTOXdfVy1LZw?oc=5", "source_name": "Elicio Therapeutics", "published_at": "2024-03-18T07:00:00+00:00", "published_display": "18 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elicio Therapeutics (ELTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBOaTJIWU13SENWdHkzY1F4c1YwelA1WUxyeUxVZjV5V3pxQkNjSkN0X1FEN0p0amZvU3lITXFuWm1HMHlfOFdTaTlnUG5ad3pkeE90MmFQOGFyUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-07-27T14:57:04+00:00", "published_display": "27 Jul 2021 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 53, "sentiment_summary": {"positive": 11, "negative": 13, "neutral": 29, "score": 48, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 13}, "market_context": {"has_market_context": true, "latest_close": 3.48, "latest_week": "2026-07-10", "one_week_move": 8.1, "four_week_move": -76.6, "twelve_week_move": -74.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.150022, "market_dynamics_buy_signal": false, "relative_strength": -69.124876, "fair_value_gap": -53.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 52.9536, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.1% over one week, -76.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "The National Law Review", "count": 3}, {"label": "ACCESS Newswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+8.1% over one week, -76.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to revenue forward of Elicio Therapeutics, Inc. \u2013 NASDAQ:ELTX"}], "updated_at": "2026-07-16T05:53:15.273598+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}